Discovery Antibodies/(S)(-)-Bay K8644/50 mg/B-351-50 mg

价格
¥9880.00
货号:B-351-50mg
浏览量:127
品牌:Discovery
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Cat #: B-351
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 356.3
    Purity: >98% (HPLC)
    Form Lyophilized powder.
    Effective concentration 50 nM - 5 µM.
      • (S)(-)-Bay K8644
    Chemical name (4S)-1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester.
    Molecular formula C16H15 F3N2O4.
    CAS No.: 98625-26-4.
    Activity (S)(-)-Bay K8644 is an L-type Ca2+-channel activator. It displays vasoconstrictive effects in vivo1.
      • Franckowiak, G. et al. (1985) Eur. J. Pharmacol. 114, 223.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility 100 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • (S)(-)-Bay K8644
        Alomone Labs (S)(-)-Bay K8644 increases L-type CaV channel currents heterologously expressed in Xenopus oocytes.
        A. Time course of CaV1.2 (co-expressed with α2δ1 and β1 auxiliary subunits) peak current amplitude, elicited by 100 ms voltage ramp from holding potential of -100 mV to +50 mV, delivered every 10 seconds. Application of 0.1 and 1 µM (S)(-)-Bay K8644 (#B-351) increases the CaV1.2 current (indicated by the horizontal bar). B. Representative current traces before and during application of 0.1 and 1 µM (S)(-)-Bay K8644 as indicated.
    References - Scientific background
    • 1. Hadley, R.W. and Hume, J.R. (1988) Circ. Res62, 97.
    • 2. Wei, X.Y. et al. (1986) J. Pharmacol. Exp. Ther239, 144.
      • (S)(-)-Bay K8644 is an L-type Ca2+-channel activator with positive inotropic, vasoconstrictive and behavioral effects in vivo. It is an enantiomer of (±)-Bay K8644. (S)(-)-Bay K8644 is a dihydropyridine that can, among other effects, constrict blood vessels and increase the force of contraction of the heart. The drug is thought to increase the entry of Ca2+ into cells by increasing the open-state probability of Ca2+ channels, either by prolonging the duration of individual openings or by increasing the number of openings. It was noted in early experiments with Bay K8644 that the dose-response curve is biphasic1. The action of (S)(-)-Bay K8644 was studied in rat tail artery and guinea pig ileal longitudinal smooth muscle using pharmacologic and radioligand binding assays. It induced concentration-dependent contractions in both smooth muscle preparations with EC50 values of 1.98-11 nM. With increasing concentrations, (S)(-)-Bay K8644 relaxed the tissue with IC50 values of 0.53-2.60 μM2.
    Target L-type Ca2+ channels
    receive a 1 mg free trial sample!
    Last update: 24/09/2019

    (S)(-)-Bay K8644 (#B-351) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Discovery®抗体是Cambridge Research Biochemicals的目录抗体业务。 CRB是全球第二大最古老的肽公司,也是抗体研究市场的先驱,目前正以Discovery®Antibodies的名义建立一系列新验证的靶标抗体。 Discovery®抗体将专注于研究用抗体(早期药物“发现”),并将补充我们非常成功且长期存在的定制抗体业务(www.crbdiscovery.com)。我们已经以新颖,复杂,稀有和翻译后修饰的特异性抗体而闻名,这些受追捧的靶标将出现在我们的Discovery®Antibody目录范围内。  我们于2017年2月,在发现肽之后一年,并且在詹姆斯·库克船长(他当时最伟大的探险家)于1776年从英国出发,乘坐“ HMS发现”号开始租用新水域和“发现全球各地的新土地。因此,“发现”这个名称似乎适合东北制造商–詹姆斯·库克的故乡。 在1700年代后期对全球新发现土地的追求与医学研究的新“发现”以及2000年人类基因组图谱的发现之间,还有其他相似之处。  有关更多详细信息,请参见有关Discovery®抗体发布的新闻稿。   Cambridge Research Biochemicals  (www.crbdiscovery.com)成立于1980年,是英国领先的定制肽和抗体工具的独立生产商,为全球制药,生命科学和学术领域的研究人员提供产品。其产品的主要应用是定制的实验室规模试剂,用于早期药物发现中的主要研究证据,并支持临床研究中的生物标志物计划。该公司生产各种口味的肽,从简单到修饰,稳定和放射性标记,再到从毫克到克到最高纯度的染料标记。此外,CRB是产生高度特异性和靶向抗体(多克隆抗体和单克隆抗体)的公认专家。荧光染料标记也是重点。自1994年以来,该公司于2016年启动了其首个目录业务DISCOVERY®。
    • 资质认证

      获得国家资质,权威认证!

    • 全国联保

      全国联保,官方无忧售后

    • 正规发票

      正规发票,放心购买

    • 签订合同

      签订合同,保障您的权益

    /**/